Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript
05:35pm, Tuesday, 09'th Jan 2024
Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript
7 Rock-Solid Healthcare Dividend Stocks to Buy in January
09:10am, Saturday, 06'th Jan 2024
The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi
AstraZeneca, Sanofi's RSV infant shots approved in China
02:13am, Tuesday, 02'nd Jan 2024
AstraZeneca and Sanofi's respiratory syncytial virus (RSV) immunization for infants has been approved in China, the London-listed drugmaker said on Tuesday.
Here's Why Sanofi (SNY) is a Strong Value Stock
11:17am, Monday, 01'st Jan 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12:03pm, Sunday, 17'th Dec 2023
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital
FTC vs Big Pharma: Sanofi drops Maze deal
02:02pm, Tuesday, 12'th Dec 2023
The Federal Trade Commission has been scrutinizing Big Pharma deals, finally scoring a win with Sanofi (SNY) scrapping its proposed licensing deal with Maze Therapeutics. The FTC said it would seek to
Sanofi ends licensing deal with Maze Therapeutics after FTC action
04:42pm, Monday, 11'th Dec 2023
Sanofi SA SAN, +1.94% said late Monday it will scuttle an agreement with biotech Maze Therapeutics Inc. after federal trade regulators sought to block it, saying the deal would eliminate competition f
Sanofi terminates deal on drug license after US FTC objects
04:39pm, Monday, 11'th Dec 2023
Sanofi said on Monday it was terminating a deal to exclusively license a drug that Maze Therapeutics is developing to treat Pompe disease because of objections from the U.S. government.
6 Health Care Dividend Stocks To By Hand Over Fist
10:48am, Monday, 11'th Dec 2023
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
04:33pm, Thursday, 07'th Dec 2023
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immuno
Sanofi to boost drug development spend by 700 mln euros in 2024
08:10am, Thursday, 07'th Dec 2023
Sanofi said it would spend close to 700 million euros ($754 million) more on drugs development next year, specifying for the first time an increase in costs that roiled investors and triggered a sell-
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
10:32pm, Wednesday, 06'th Dec 2023
Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while boo
Sanofi CEO under pressure to woo investors after spending shock
01:02am, Tuesday, 05'th Dec 2023
Sanofi's CEO is under pressure to tell investors how much more he will spend on research and development (R&D) and what the likely pay-offs will be, as he seeks to boost a pipeline of future drugs and
Buy These 3 Deep Value, A-Rated Dividend Stocks Hand Over Fist
07:05am, Monday, 04'th Dec 2023
Here are three undervalued stocks with promising growth potential and high-quality A-rated balance sheets. It's just one of three incredible opportunities that combine to create a 16% annual return po
Sanofi: A Shift In The Story
01:23am, Tuesday, 28'th Nov 2023
Limited pipeline catalysts until 2025 mean a "show me" story status. Higher R&D costs and uncertainty for the future. A new spin-off in the consumer division with no 2025 profitability targets. Sanofi
